Georgia is currently home to 2004 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Atlanta, Augusta, Decatur and Savannah. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm
NCT05027997
Recruiting
This study is designed to assess the safety and tolerability of dipraglurant in patients with blepharospasm (BSP) (randomized 1:1:1 to receive dipraglurant 50 mg, 100 mg or placebo) and explore the efficacy of 50 mg and 100 mg immediate release tablets (versus placebo) on the severity and frequency of BSP signs and symptoms using objective measures, clinical ratings and patient reported outcomes.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
11/01/2021
Locations: Emory University, Atlanta, Georgia
Conditions: Blepharospasm, Dystonia
Register for Updates
Intervention to Improve HIV Care Retention by Addressing Stigma Stigmatized Environments
NCT05110963
Recruiting
Retention in care and persistent adherence to antiretroviral therapy are necessary for the successful treatment of HIV infection. HIV-related stigma is a known impediment to the care and health outcomes of people living with HIV. The proposed study will test theory-based interventions designed to manage HIV stigma in order to improve care retention and medication adherence in communities with high-levels of HIV-related stigma.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/28/2021
Locations: University of Connecticut Field Site, Atlanta, Georgia
Conditions: HIV I Infection
Register for Updates
HIV Treatment Adherence Dose Determination Trial
NCT04577313
Recruiting
The proposed research will conduct the first dose-determination trial to find the optimal number of behavioral counseling sessions (dose) needed to achieve and sustain optimal HIV treatment adherence. The results of this study will determine how much intervention is needed for whom and at what cost to guide health policy and implementation of behavioral interventions designed to improve durable viral suppression.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/13/2021
Locations: University of Connecticut Field Site, Atlanta, Georgia
Conditions: HIV Infections
Register for Updates
Dietary Oxysterols and β-Cell Function Among African Americans
NCT05072587
Recruiting
African Americans (AAs) have a higher risk of developing type 2 diabetes than the general population. AAs are also more likely to eat foods that contain cholesterol oxides/oxysterols. Dietary oxysterols can harm the cells that produce insulin and decrease insulin production. This pilot study seeks to determine if removing dietary oxysterols with a plant-based diet will improve insulin production and decrease the risk of type 2 diabetes among AAs.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/08/2021
Locations: Morehouse School of Medicine, Atlanta, Georgia
Conditions: Type 2 Diabetes
Register for Updates
Continuous Monitoring and Control of Hypoglycemia
NCT03340831
Recruiting
Evaluate safety of non-adjunctive CGM use in CGM naive participants.
Gender:
All
Ages:
2 years and above
Trial Updated:
09/17/2021
Locations: Atlanta Diabetes, Atlanta, Georgia
Conditions: Diabetes
Register for Updates
Myeloma-Developing Regimens Using Genomics (MyDRUG)
NCT03732703
Recruiting
The MyDRUG study is a type of Precision Medicine trial to treat patients with drugs targeted to affect specific genes that are mutated as part of the disease. Mutations in genes can lead to uncontrolled cell growth and cancer. Patients with a greater than 25% mutation to any of the following genes; CDKN2C, FGFR3, KRAS, NRAS, BRAF V600E, IDH2 or T(11;14) can be enrolled to one of the treatment arms. These arms have treatments specifically directed to the mutated genes. Patients that do not have a... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
09/09/2021
Locations: Emory University, Atlanta, Georgia
Conditions: Relapsed Refractory Multiple Myeloma
Register for Updates
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
NCT03509961
Recruiting
This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hematopoietic cell transplant (HCT). Patients diagnosed with B-ALL who are candidates for HCT will be screened by NGS-MRD on a test of bone marrow done before the HCT. Subjects who are pre-HCT NGS-MRD negative will be eligible to receive a non-TBI conditioning regime... Read More
Gender:
All
Ages:
Between 1 year and 25 years
Trial Updated:
08/20/2021
Locations: Children's Healthcare of Atlanta, Atlanta, Georgia
Conditions: B-cell Acute Lymphoblastic Leukemia
Register for Updates
Use of Repris Needle in Bladder Injection
NCT04982120
Recruiting
Treatment of overactive bladder (OAB) has been treated successfully by the injection of Botox. The Repris injection needle has a deflection that may assist in injection difficult to reach with standard straight needles. This study will assess the success, safety and patient tolerance of this new injection needle.
Gender:
Female
Ages:
18 years and above
Trial Updated:
07/28/2021
Locations: Georgia Urology, Cartersville, Georgia
Conditions: Overactive Bladder Syndrome
Register for Updates
Assessment of VMCore Biopsy Versus Standard of Care Biopsy
NCT04982536
Recruiting
Prostate biopsy is the definitive test to establish the diagnosis of prostate cancer. The standard of care biopsy needles do not predictably obtain full cores of tissue and what tissue obtained is often fragmented, making pathologic review a challenge. The VMCore Biopsy System has a geometry in the tip of its biopsy needles that capture more tissue in a single sample. This study is to compare the characteristics of tissue captured by either standard of care needles and the VMCore needle.
Gender:
Male
Ages:
18 years and above
Trial Updated:
07/28/2021
Locations: Georgia Urology, Cartersville, Georgia
Conditions: Prostate Cancer
Register for Updates
Salt and Gut Study
NCT04958148
Recruiting
High sodium intake is a significant risk factor for hypertension. Recently, animal studies connect high sodium intake to the gut-immune axis and highlight the gut microbiome as a potential therapeutic target to counteract salt-sensitive conditions and hypertension. The objective of this project is to determine the effects of high salt intake on gut microbiota composition and gut intestine barrier integrity, leading to increased BP in humans. The investigators also hypothesize that high salt inta... Read More
Gender:
All
Ages:
Between 18 years and 50 years
Trial Updated:
06/29/2021
Locations: Georgia Prevention Institute/ Augusta University, Augusta, Georgia
Conditions: High Blood Pressure
Register for Updates
Multi-Center Study to Evaluate the Efficacy and Safety of Sildenafil Cream (3.6%) in Premenopausal Patients With Female Sexual Arousal Disorder
NCT04948151
Recruiting
This study is looking to minimize side effects, while maintaining and potentially improving the therapeutic benefit to patients suffering from Female Sexual Arousal Disorder by providing a topical preparation of Sildenafil locally to the vulvar-vaginal tissue.
Gender:
Female
Ages:
21 years and above
Trial Updated:
06/24/2021
Locations: AGILE Clinical Research Trials, Atlanta, Georgia
Conditions: Female Sexual Arousal Disorder
Register for Updates
An Extension Study to Evaluate the Efficacy and Safety of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS
NCT02633683
Recruiting
The objectives of the trial are to evaluate the long-term efficacy and safety of HORIZANT (Gabapentin Enacarbil) 600 mg daily, for the treatment of RLS in adolescents (13 to 17 years of age) diagnosed with moderate-to-severe primary RLS.
Gender:
All
Ages:
Between 13 years and 17 years
Trial Updated:
06/07/2021
Locations: Clinical Integrative Research Center of Atlanta, INC, Atlanta, Georgia
Conditions: RLS
Register for Updates